This disclosure relates to modulators of liver receptor homologue 1 (LRH-1) and methods of managing disease and conditions related thereto. In certain embodiments, modulators are derivatives of hexahydropentalene. In certain embodiments, this disclosure relates to methods of treating or preventing cancer, diabetes, or cardiovascular disease by administering an effective amount of a hexahydropentalene derivative disclosed herein.

This disclosure relates to modulators of liver receptor homologue 1 (LRH-1) and methods of managing disease and conditions related thereto. In certain embodiments, modulators are derivatives of hexahydropentalene. In certain embodiments, this disclosure relates to methods of treating or preventing cancer, diabetes, or cardiovascular disease by administering an effective amount of a hexahydropentalene derivative disclosed herein.

Provided herein are solid forms comprising (a) 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and (b) a coformer. Pharmaceutical compositions comprising the solid forms (e.g., cocrystals) and methods for treating, preventing and managing various disorders are also disclosed.

Provided herein are solid forms comprising (a) 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and (b) a coformer. Pharmaceutical compositions comprising the solid forms (e.g., cocrystals) and methods for treating, preventing and managing various disorders are also disclosed.

The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof and pharmaceutical compositions comprising the same.

The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof and pharmaceutical compositions comprising the same.

The present invention relates to thermotropic ionic liquid crystal molecules of general formula (I)

##STR00001##

With E.sub.1 and E.sub.2, which may be identical or different, representing, independently of one another, a linear, saturated and unsubstituted C.sub.10 to C.sub.14 hydrocarbon-based radical, A.sup.x representing a sulfonate anion or a sulfonylimide anion of formula SO.sub.2N.sup.SO.sub.2C.sub.yF.sub.2y+1 with y being an integer ranging from 0 to 2 and C.sup.x+ a sodium, lithium or potassium ion, most particularly advantageous for their conductivity performance qualities as an electrolyte in particular for lithium batteries.

The present invention relates to thermotropic ionic liquid crystal molecules of general formula (I)

##STR00001##

With E.sub.1 and E.sub.2, which may be identical or different, representing, independently of one another, a linear, saturated and unsubstituted C.sub.10 to C.sub.14 hydrocarbon-based radical, A.sup.x representing a sulfonate anion or a sulfonylimide anion of formula SO.sub.2N.sup.SO.sub.2C.sub.yF.sub.2y+1 with y being an integer ranging from 0 to 2 and C.sup.x+ a sodium, lithium or potassium ion, most particularly advantageous for their conductivity performance qualities as an electrolyte in particular for lithium batteries.

Here are described processes for the preparation of sulfamic acid derivatives, for instance, halogenated derivatives and their metallic or organic salts. The present document also describes the sulfamic acid derivatives thus produced and to their uses, for instance, in electrolyte compositions for electrochemical applications.

Here are described processes for the preparation of sulfamic acid derivatives, for instance, halogenated derivatives and their metallic or organic salts. The present document also describes the sulfamic acid derivatives thus produced and to their uses, for instance, in electrolyte compositions for electrochemical applications.